<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3538">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 19, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01923129</url>
  </required_header>
  <id_info>
    <org_study_id>00029210</org_study_id>
    <nct_id>NCT01923129</nct_id>
  </id_info>
  <brief_title>Optimal Duration of Indwelling Urinary Catheter Following Pelvic Surgery</brief_title>
  <official_title>Prospective Study Investigating Optimal Duration of Indwelling Urinary Catheter Following Infraperitoneal Colorectal Surgery and Role of Postoperative Alpha Blockade</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is no general agreement about the optimal duration of postoperative urinary drainage,&#xD;
      with relevant literature reporting durations ranging from 1 to 10 days. The available&#xD;
      research supporting the routine use of prolonged catheterization is limited and studies&#xD;
      investigating early removal following infraperitoneal colorectal surgery have largely been&#xD;
      underpowered to form valid practice conclusions. The aim of the investigators study is to&#xD;
      determine whether a postoperative colorectal patient can safely have an indwelling catheter&#xD;
      removed on postoperative day one (24 hours following surgery) with the addition of a study&#xD;
      medication (prazosin), without a statistically significant difference in the incidence of&#xD;
      urinary retention compared to the standard, accepted approach of delayed removal (72 hours&#xD;
      postoperatively). Patients undergoing laparoscopic and open pelvic colorectal surgery below&#xD;
      the peritoneal reflection for both benign and malignant conditions will be randomized into&#xD;
      two groups: group one will have the catheter removed on postoperative day 3 (72 hours&#xD;
      postoperatively) Group 2 will have a dose of the alpha-blocker prazosin given 6 hours prior&#xD;
      to catheter removal and will have the urinary catheter removed on postoperative day 1 (24&#xD;
      hours postoperatively).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The available research supporting the routine use of prolonged catheterization is limited and&#xD;
      studies investigating early removal following infraperitoneal colorectal surgery have largely&#xD;
      been underpowered to form valid practice conclusions. In the era of multimodal recovery&#xD;
      algorithms emphasizing early diet advancement, ambulation, and shorter hospital length of&#xD;
      stay, unnecessarily prolonging catheterization may interfere with many of these objectives.&#xD;
      An indwelling urinary catheter interferes with early patient mobilization potentially&#xD;
      lengthening hospitalization and subjects patients to an increased risk of urinary tract&#xD;
      infection. A study of 2,355 consecutive patients undergoing primary colorectal cancer&#xD;
      resection via laparotomy found an overall prevalence of postoperative urinary retention of&#xD;
      5.5%, however, those patients undergoing low pelvic surgery experience an almost 16%&#xD;
      incidence in urinary retention.&#xD;
&#xD;
      Postoperative urinary catheter drainage after infraperitoneal colorectal surgery is commonly&#xD;
      practiced, assuming some degree of nerve damage to the superior hypogastric plexus at the&#xD;
      sacral promontory or of the nervi erigentes at the pelvic side wall resulting from pelvic&#xD;
      dissection, causing transient or permanent dysfunction of the lower urinary tract. It has&#xD;
      been believed that this intraoperative damage to the pelvic autonomic nerves may be&#xD;
      associated with early postoperative acute urinary retention, and justifies an indwelling&#xD;
      urinary catheter for several days following infraperitoneal pelvic surgery. However, there is&#xD;
      no general agreement about the optimal duration of postoperative urinary drainage, with&#xD;
      relevant literature reporting durations ranging from 1 to 10 days.&#xD;
&#xD;
      Prolonged indwelling urinary catheter has been associated with increased risk of urinary&#xD;
      tract infections, with the risk of bacteriuria between 3 and 10% per day when catheterized,&#xD;
      with the risk of urinary tract infection increasing by 5% to 10% per catheter day after the&#xD;
      second day of catheterization. The incidence of urinary tract infections after anorectal&#xD;
      surgery and 5 days of catheterization has been shown to range between 42% and 60%. Higher&#xD;
      mortality rates have been reported in hospitalized patients who developed urinary tract&#xD;
      infection after indwelling catheterization with the incidence of bacteremia after single&#xD;
      catheterization reported to be as high as 8%.&#xD;
&#xD;
      The optimal duration of urinary drainage after infraperitoneal colorectal surgery is unknown.&#xD;
      Based on the autonomic mechanisms of micturition in relation to the striated muscle fibers of&#xD;
      the external urethral sphincter, alpha blockade has been studied as a potential intervention&#xD;
      to reduce the incidence of re-catheterization. A large Cochrane Database reviewed their role&#xD;
      in five randomized trials, with four trials favoring alpha blockade over placebo.&#xD;
      Furthermore, the side-effect profile of alpha-blockade was low and compared favorably to&#xD;
      placebo.&#xD;
&#xD;
      Prior studies have suggested urinary bladder catheter drainage removed on postoperative day&#xD;
      one following pelvic surgery may be safe and decrease the incidence of urinary tract&#xD;
      infection. However, the study was underpowered to detect meaningful conclusions. A larger&#xD;
      study investigating the optimal duration of urinary drainage concluded that removing the&#xD;
      catheter one day postoperatively in patients undergoing infraperitoneal colorectal surgery is&#xD;
      appropriate, unless a low rectal carcinoma is present or lymph node metastatic disease is&#xD;
      present. The investigators wish to further substantiate this evidence and introduce the&#xD;
      positive findings associated with alpha-blockade in minimizing the need for&#xD;
      re-catheterization.&#xD;
&#xD;
      The investigators therefore propose a prospective, controlled randomized trial to compare the&#xD;
      effects of 1 day's transurethral catheterization after infraperitoneal surgery with an alpha&#xD;
      blockade medication compared to those of 3 days of catheterization, with acute urinary&#xD;
      retention as a primary endpoint.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 30, 2012</start_date>
  <completion_date type="Actual">November 22, 2017</completion_date>
  <primary_completion_date type="Actual">November 22, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Acute Urinary Retention</measure>
    <time_frame>Postoperative day 1 or postpoperative 3 depending on group randomization</time_frame>
    <description>Acute urinary retention will be defined as catheter discontinuation with inability to void 6 hours post-removal, or void with post-void residual greater than 200 cc of urine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Symptomatic Urinary Tract Infection</measure>
    <time_frame>During 1 week of hospitalization (prior to discharge)</time_frame>
    <description>Urinary tract infection defined as symptomatic urinary complaints such as dysuria, with urinalysis consistent with infection.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">142</enrollment>
  <condition>Urinary Retention</condition>
  <arm_group>
    <arm_group_label>24 hour postop catheter removal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>group will receive the study medication prazosin ( 1 mg PO) 6 hours prior to catheter discontinuation (24 hours postoperatively)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>72 hour postoperative catheter removal</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>catheter removed on postoperative day 3 (72 hours postoperatively)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prazosin given 6 hours prior to catheter removal in the 24 hour group</intervention_name>
    <description>Prazosin given orally (1 mg) 6 hours prior to catheter removal (hour 18 postoperatively)</description>
    <arm_group_label>24 hour postop catheter removal</arm_group_label>
    <other_name>Minipress</other_name>
    <other_name>Vasoflex</other_name>
    <other_name>Pressin</other_name>
    <other_name>Hypovase</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to freely give written informed consent to participate in the study and have&#xD;
             signed the Informed Consent Form;&#xD;
&#xD;
          2. Males or females, &gt;18 years of age inclusive at the time of study screening;&#xD;
&#xD;
          3. American Society of Anesthesiologists (ASA) Class I-III;&#xD;
&#xD;
          4. Infraperitoneal colorectal surgery (open and/or laparoscopic);&#xD;
&#xD;
          5. Elective Surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Mentally incompetent or unable or unwilling to provide informed consent or comply with&#xD;
             study procedures;&#xD;
&#xD;
          2. Children &lt;18;&#xD;
&#xD;
          3. No perioperative antibiotics;&#xD;
&#xD;
          4. Past or current urinary tract malignancy;&#xD;
&#xD;
          5. Urinary catheter inserted before surgery;&#xD;
&#xD;
          6. Chronic kidney insufficiency with Creatinine&gt; 2&#xD;
&#xD;
          7. Diagnosis of benign prostatic hyperplasia&#xD;
&#xD;
          8. Chronic urinary infections&#xD;
&#xD;
          9. Neurogenic bladder&#xD;
&#xD;
         10. History of enterovesical fistula&#xD;
&#xD;
         11. Pregnancy&#xD;
&#xD;
         12. Prior surgery of the lower urinary tract&#xD;
&#xD;
         13. Epidural&#xD;
&#xD;
         14. Perioperative ureteral stents&#xD;
&#xD;
        After randomization:&#xD;
&#xD;
          1. Catheter pulled out inadvertently;&#xD;
&#xD;
          2. Postoperative complications requiring prolonged monitoring of urine output&#xD;
&#xD;
          3. Postoperative complications requiring early reoperation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phillip Fleshner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>July 29, 2013</study_first_submitted>
  <study_first_submitted_qc>August 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2013</study_first_posted>
  <results_first_submitted>October 26, 2018</results_first_submitted>
  <results_first_submitted_qc>January 30, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 20, 2019</results_first_posted>
  <last_update_submitted>January 30, 2019</last_update_submitted>
  <last_update_submitted_qc>January 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Phillip Fleshner MD</investigator_full_name>
    <investigator_title>Widjaja Chair in Colorectal Surgery</investigator_title>
  </responsible_party>
  <keyword>indwelling catheter</keyword>
  <keyword>foley</keyword>
  <keyword>duration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Retention</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prazosin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 30, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT01923129/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 30, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT01923129/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>5 subjects were excluded.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>24 Hour Postop Catheter Removal</title>
          <description>group will receive the study medication prazosin ( 1 mg PO) 6 hours prior to catheter discontinuation (24 hours postoperatively)&#xD;
Prazosin given 6 hours prior to catheter removal in the 24 hour group: Prazosin given orally (1 mg) 6 hours prior to catheter removal (hour 18 postoperatively)</description>
        </group>
        <group group_id="P2">
          <title>72 Hour Postoperative Catheter Removal</title>
          <description>catheter removed on postoperative day 3 (72 hours postoperatively)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>24 Hour Postop Catheter Removal</title>
          <description>group will receive the study medication prazosin ( 1 mg PO) 6 hours prior to catheter discontinuation (24 hours postoperatively)&#xD;
Prazosin given 6 hours prior to catheter removal in the 24 hour group: Prazosin given orally (1 mg) 6 hours prior to catheter removal (hour 18 postoperatively)</description>
        </group>
        <group group_id="B2">
          <title>72 Hour Postoperative Catheter Removal</title>
          <description>catheter removed on postoperative day 3 (72 hours postoperatively)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="71"/>
            <count group_id="B2" value="71"/>
            <count group_id="B3" value="142"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.07" spread="16.9"/>
                    <measurement group_id="B2" value="45.6" spread="17.8"/>
                    <measurement group_id="B3" value="44.8" spread="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="117"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.4" spread="4.9"/>
                    <measurement group_id="B2" value="23.78" spread="4.2"/>
                    <measurement group_id="B3" value="24.1" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>American Society of Anesthesiologists Physical Status Classification</title>
          <description>ASA I A normal healthy patient&#xD;
ASA II A patient with mild systemic disease Mild diseases only without substantive functional limitations.&#xD;
ASA III A patient with severe systemic disease Substantive functional limitations; One or more moderate to severe diseases.&#xD;
ASA IV A patient with severe systemic disease that is a constant threat to life</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Surgery Indication</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>inflammatory bowel disease</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Cancer</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Prolapse</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of Surgery</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>IPAA</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
                <category>
                  <title>LAR</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Rectopexy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Surgical drain</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="123"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>intraoperative intravenous fluids</title>
          <description>This is crystalloids received via intravenous access during surgery</description>
          <units>milliliters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2855.6" spread="803"/>
                    <measurement group_id="B2" value="2948.6" spread="857"/>
                    <measurement group_id="B3" value="2901" spread="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>intraoperative estimated blood loss</title>
          <description>A clinical estimate of surgical blood loss determined by the lead surgeon and anesthesiologist after the conclusion of the case.</description>
          <units>milliliters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="182" spread="82"/>
                    <measurement group_id="B2" value="201" spread="99"/>
                    <measurement group_id="B3" value="192" spread="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>OR time</title>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="282" spread="66"/>
                    <measurement group_id="B2" value="301" spread="61"/>
                    <measurement group_id="B3" value="292" spread="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>peri-operative blood transfusion</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>no</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total mesorectal excision</title>
          <description>Total mesorectal excision (TME) employs a precise, sharp dissection between the visceral and parietal layers of the endopelvic fascia to ensure en bloc removal of the perirectal areolar tissue, including the lateral and circumferential margins of the mesorectal envelope, lymphatics, and vascular/perineural tumor deposits with the primary rectal cancer. TME also preserves the autonomic nerves and reduces the risk of presacral bleeding.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>no</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>neoadjuvant chemotherapy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>no</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>intravenous pain medications on post-operative day one</title>
          <description>in the immediate 24 hours following surgery, the total amount of intravenous narcotics consumed by the patient was recorded and collected. All intravenous narcotics were converted into equivalent milligrams of hydromorphone.</description>
          <units>milligrams of hydromorphone</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.6" spread="1.73"/>
                    <measurement group_id="B2" value="4.8" spread="1.65"/>
                    <measurement group_id="B3" value="4.7" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>mean pain score</title>
          <description>This is a 1-10 scale Pain 0: No pain at all, you feel perfectly normal. Pain 1: Very light barely noticeable pain Pain 2: Minor pain, Discomforting Pain 3: Tolerable pain Pain 4: Distressing, Strong, deep pain Pain 5: Very Distressing, Strong, deep, piercing pain Pain 6: Intense Pain deep, piercing pain so strong it seems to partially dominate your senses Pain 7: Very Intense Pain Pain 8: Horrible Pain: so intense you can no longer think clearly at all Pain 9: Excruciating, so intense you cannot tolerate Pain 10: Unimaginable Pain, so intense you will go unconscious shortly.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.84" spread="1.09"/>
                    <measurement group_id="B2" value="3.91" spread="1.09"/>
                    <measurement group_id="B3" value="3.87" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>The tumor, node, metastasis (TNM) staging system of the combined American Joint Committee on Cancer</title>
          <description>This is a staging system from stage 0 (best, no tumor) to stage 4 (worst, metastatic disease).&#xD;
T = tumor stage (T1 is best and invades submucosa, T2 invades muscularis, T3 invades pericolorectal tissues, T4 is worst and adherent to other organs N = nodal stage (N0 negative nodes is best, N+ positive nodes is worse) M = metastases stage (M0 no metastases is best, M+ metastases is worse)&#xD;
The categories are:&#xD;
0: T0, N0, M0&#xD;
T1-T2, N0, M0&#xD;
T3-T4, N0, M0&#xD;
Any T stage, N+, M0&#xD;
Any T or N stage, M+</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="108"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2A</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2B</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2c</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3a</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3b</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Acute Urinary Retention</title>
        <description>Acute urinary retention will be defined as catheter discontinuation with inability to void 6 hours post-removal, or void with post-void residual greater than 200 cc of urine.</description>
        <time_frame>Postoperative day 1 or postpoperative 3 depending on group randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>24 Hour Postop Catheter Removal</title>
            <description>group will receive the study medication prazosin ( 1 mg PO) 6 hours prior to catheter discontinuation (24 hours postoperatively)&#xD;
Prazosin given 6 hours prior to catheter removal in the 24 hour group: Prazosin given orally (1 mg) 6 hours prior to catheter removal (hour 18 postoperatively)</description>
          </group>
          <group group_id="O2">
            <title>72 Hour Postoperative Catheter Removal</title>
            <description>catheter removed on postoperative day 3 (72 hours postoperatively)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Acute Urinary Retention</title>
          <description>Acute urinary retention will be defined as catheter discontinuation with inability to void 6 hours post-removal, or void with post-void residual greater than 200 cc of urine.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Symptomatic Urinary Tract Infection</title>
        <description>Urinary tract infection defined as symptomatic urinary complaints such as dysuria, with urinalysis consistent with infection.</description>
        <time_frame>During 1 week of hospitalization (prior to discharge)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>24 Hour Postop Catheter Removal</title>
            <description>group will receive the study medication prazosin ( 1 mg PO) 6 hours prior to catheter discontinuation (24 hours postoperatively)&#xD;
Prazosin given 6 hours prior to catheter removal in the 24 hour group: Prazosin given orally (1 mg) 6 hours prior to catheter removal (hour 18 postoperatively)</description>
          </group>
          <group group_id="O2">
            <title>72 Hour Postoperative Catheter Removal</title>
            <description>catheter removed on postoperative day 3 (72 hours postoperatively)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Symptomatic Urinary Tract Infection</title>
          <description>Urinary tract infection defined as symptomatic urinary complaints such as dysuria, with urinalysis consistent with infection.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The primary outcome of interest was the rate of AUR, defined as the number of patients with AUR within each study group. A 15% non-inferiority margin was chosen according to clinical relevance estimation. The expected difference between the two groups was 0%. Non-inferiority analysis was performed by calculation of risk difference and its 95% confidence interval according to Newcombe &amp; Altman.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>72 hours</time_frame>
      <desc>Methods did not differ from definitions provided by clinicaltrials.gov</desc>
      <group_list>
        <group group_id="E1">
          <title>24 Hour Postop Catheter Removal</title>
          <description>group will receive the study medication prazosin ( 1 mg PO) 6 hours prior to catheter discontinuation (24 hours postoperatively)&#xD;
Prazosin given 6 hours prior to catheter removal in the 24 hour group: Prazosin given orally (1 mg) 6 hours prior to catheter removal (hour 18 postoperatively)</description>
        </group>
        <group group_id="E2">
          <title>72 Hour Postoperative Catheter Removal</title>
          <description>catheter removed on postoperative day 3 (72 hours postoperatively)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="71"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Phillip Fleshner</name_or_title>
      <organization>Cedars Sinai Medical Center</organization>
      <phone>(310) 289-9224</phone>
      <email>Phillip.Fleshner@cshs.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

